205 related articles for article (PubMed ID: 15230667)
1. Predictors of response to infliximab in patients with fistulizing Crohn's disease.
Luna-Chadid M; Pérez Calle JL; Mendoza JL; Vera MI; Bermejo AF; Sánchez F; López San Román A; Froilán C; González-Lara V; García-Paredes J; Fernández-Blanco I; Abreu L; Casis B; Solís Herruzo JA; Gisbert JP; Maté Jiménez J
Rev Esp Enferm Dig; 2004 Jun; 96(6):379-81; 382-4. PubMed ID: 15230667
[TBL] [Abstract][Full Text] [Related]
2. Infliximab in treatment of Crohn's disease: the Milan experience.
Ardizzone S; Colombo E; Maconi G; Bollani S; Manzionna G; Petrone MC; Bianchi Porro G
Dig Liver Dis; 2002 Jun; 34(6):411-8. PubMed ID: 12132788
[TBL] [Abstract][Full Text] [Related]
3. Remicade does not abolish the need for surgery in fistulizing Crohn's disease.
Poritz LS; Rowe WA; Koltun WA
Dis Colon Rectum; 2002 Jun; 45(6):771-5. PubMed ID: 12072629
[TBL] [Abstract][Full Text] [Related]
4. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience.
Topstad DR; Panaccione R; Heine JA; Johnson DR; MacLean AR; Buie WD
Dis Colon Rectum; 2003 May; 46(5):577-83. PubMed ID: 12792431
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab.
Bouguen G; Siproudhis L; Gizard E; Wallenhorst T; Billioud V; Bretagne JF; Bigard MA; Peyrin-Biroulet L
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):975-81.e1-4. PubMed ID: 23376316
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
7. Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine.
Schröder O; Blumenstein I; Schulte-Bockholt A; Stein J
Aliment Pharmacol Ther; 2004 Feb; 19(3):295-301. PubMed ID: 14984376
[TBL] [Abstract][Full Text] [Related]
8. Type of fistula determines response to infliximab in patients with fistulous Crohn's disease.
Parsi MA; Lashner BA; Achkar JP; Connor JT; Brzezinski A
Am J Gastroenterol; 2004 Mar; 99(3):445-9. PubMed ID: 15056083
[TBL] [Abstract][Full Text] [Related]
9. Infliximab improves quality of life in the short-term in patients with fistulizing Crohn's disease in clinical practice.
Cadahia V; García-Carbonero A; Vivas S; Fuentes D; Niño P; Rebollo P; Rodrigo L
Rev Esp Enferm Dig; 2004 Jun; 96(6):369-74; 374-8. PubMed ID: 15230666
[TBL] [Abstract][Full Text] [Related]
10. Infliximab maintenance therapy for fistulizing Crohn's disease.
Sands BE; Anderson FH; Bernstein CN; Chey WY; Feagan BG; Fedorak RN; Kamm MA; Korzenik JR; Lashner BA; Onken JE; Rachmilewitz D; Rutgeerts P; Wild G; Wolf DC; Marsters PA; Travers SB; Blank MA; van Deventer SJ
N Engl J Med; 2004 Feb; 350(9):876-85. PubMed ID: 14985485
[TBL] [Abstract][Full Text] [Related]
11. Retreatment and maintenance therapy with infliximab in fistulizing Crohn's disease.
Rodrigo L; Pérez-Pariente JM; Fuentes D; Cadahia V; García-Carbonero A; Niño P; de Francisco R; Tojo R; Moreno M; González-Ballina E
Rev Esp Enferm Dig; 2004 Aug; 96(8):548-54; 554-8. PubMed ID: 15449986
[TBL] [Abstract][Full Text] [Related]
12. Infliximab in the surgical management of complex fistulating anal Crohn's disease.
Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D
Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356
[TBL] [Abstract][Full Text] [Related]
13. [Effectiveness of anti-TNF alpha antibodies in treatment of fistulizing Crohn's disease].
Rozpondek P; Zwolińska-Wcisło M; Przybylska M; Mach T
Przegl Lek; 2011; 68(9):602-5. PubMed ID: 22335009
[TBL] [Abstract][Full Text] [Related]
14. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ
Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
[TBL] [Abstract][Full Text] [Related]
15. Optimizing anti-TNF treatment in inflammatory bowel disease.
Rutgeerts P; Van Assche G; Vermeire S
Gastroenterology; 2004 May; 126(6):1593-610. PubMed ID: 15168370
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
Kinney T; Rawlins M; Kozarek R; France R; Patterson D
Am J Gastroenterol; 2003 Mar; 98(3):608-12. PubMed ID: 12650795
[TBL] [Abstract][Full Text] [Related]
17. Infliximab and surgical treatment of complex anal Crohn's disease.
Duff S; Sagar PM; Rao M; Dolling S; Sprakes M; Hamlin PJ
Colorectal Dis; 2012 Aug; 14(8):972-6. PubMed ID: 21899707
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of non-fistulizing (ulcers, stricture) perianal Crohn's disease in patients treated with infliximab.
Bouguen G; Trouilloud I; Siproudhis L; Oussalah A; Bigard MA; Bretagne JF; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2009 Oct; 30(7):749-56. PubMed ID: 19583709
[TBL] [Abstract][Full Text] [Related]
19. Review article: Medical therapy for fistulizing Crohn's disease.
Bressler B; Sands BE
Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
[TBL] [Abstract][Full Text] [Related]
20. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
Keating GM; Perry CM
BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
